RIDASCREEN®GLM Monitoring

Intended use:

RIDASCREEN® GLM Monitoring is an enzyme linked immunoassay intended for the quantitative determination of golimumab (GLM, Simponi®) in human serum and plasma.

General information:

Golimumab (GLM) is a human monoclonal antibody and binds to both the soluble and transmembrane bioactive forms of human TNF-alpha, giving rise to stable high-affinity complexes thereby preventing the binding of TNF-alpha to its receptors. Golimumab has been approved for the treatment of various chronic immune-mediated inflammatory disorders in which TNF-alpha plays an important role, including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis and ulcerative colitis (UC). Recent data on TDM have shown a positive relation between GLM trough serum concentrations and clinical outcomes in patients with RA3 and UC4. TDM may therefore be very instrumental to optimize treatment.
RIDASCREEN® GLM Monitoring uses a highly specific monoclonal antibody (MA-GOM171D8), which was isolated and characterized at the KU Leuven. It detects only golimumab; other anti-TNF drugs (like infliximab, adalimumab) do not interfere with the measurement.

Key features:

• CE-marked version of the ELISA tests of KU Leuven
• Highly specific antibodies
• Ready to use reagents
• Validated for use on automated ELISA systems, e.g. the Dynex DSX®